Status
Conditions
Treatments
About
Parkinson diseases (PD) is the second most common degenerative disease of the central nervous system. The development of early diagnostic biomarkers may help identify at-risk individuals and allow precocious interventions at the onset of disease and more precise monitoring of therapies that may slow disease progression.
Proof of concept studies indicated significant differences in pupil light response between PD patients and healthy controls. The feasibility of using pupillometry for assesment of PD will be examined.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
General inclusion criteria
Patients' Inclusion Criteria:
Patients with clinical presentations of the neurodegenerative forms of parkinsonism (bradykinesia, extrapyramidal rigidity, tremor, postural instability and gait disturbance) including: idiopathic Parkinson disease (PD), Lewy body disease (LBD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD) and secondary parkinsonisms.
Control group- inclusion criteria
Normal eye examination
Best-corrected visual acuity (BCVA) of 20/20
Normal color vision test (Farnsworth/Lanthon D-15 Test)
No present ocular disease
No past ocular disease or surgery within last 6 months
No use of any topical or systemic medications that could adversely influence efferent pupil movements
Normal 24-2 Humphrey visual field and
Exclusion criteria
200 participants in 2 patient groups
Loading...
Central trial contact
Lori Gueta
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal